Revolution Medicines, Inc.
RVMD
$39.12
$0.090.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 742.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 742.00K |
| Cost of Revenue | 188.10M | 151.75M | 12.78M | 118.02M | 136.58M |
| Gross Profit | -188.10M | -151.75M | -12.78M | -118.02M | -135.84M |
| SG&A Expenses | 28.21M | 23.96M | 21.71M | 22.84M | 18.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.31M | 175.71M | 156.64M | 140.86M | 155.23M |
| Operating Income | -216.31M | -175.71M | -156.64M | -140.86M | -154.48M |
| Income Before Tax | -195.32M | -156.29M | -133.23M | -116.00M | -161.19M |
| Income Tax Expenses | -753.00K | -- | -- | -- | 343.00K |
| Earnings from Continuing Operations | -194.57M | -156.29M | -133.23M | -116.00M | -161.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -194.57M | -156.29M | -133.23M | -116.00M | -161.54M |
| EBIT | -216.31M | -175.71M | -156.64M | -140.86M | -154.48M |
| EBITDA | -214.61M | -174.10M | -154.93M | -139.35M | -153.17M |
| EPS Basic | -1.12 | -0.94 | -0.81 | -0.70 | -1.14 |
| Normalized Basic EPS | -0.70 | -0.59 | -0.50 | -0.43 | -0.60 |
| EPS Diluted | -1.12 | -0.94 | -0.81 | -0.70 | -1.14 |
| Normalized Diluted EPS | -0.70 | -0.59 | -0.50 | -0.43 | -0.60 |
| Average Basic Shares Outstanding | 173.76M | 166.84M | 165.14M | 164.73M | 141.18M |
| Average Diluted Shares Outstanding | 173.76M | 166.84M | 165.14M | 164.73M | 141.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
